Thoas Fioretos

Thoas Fioretos

Auto-generated profile, based on publicly available information

Thoas Fioretos

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2015 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
FMFredrik Mertens
Fredrik Mertens
BJBertil Johansson
Bertil Johansson
TFThoas Fioretos
Thoas Fioretos
FMFelix Mitelman
Felix Mitelman

2 March 2015 in Nature Genetics
Verified
Journal Article
Open access
PDF file
FPfor The St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project
for The St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project
AAAnna K Andersson
Anna K Andersson
JMJing Ma
Jing Ma
JWJianmin Wang
Jianmin Wang
XCXiang Chen
Xiang Chen
JDJames R Downing
James R Downing
Anna Andersson, Tanja Gruber, James Downing and colleagues report a genomic analysis of infant acute lymphoblastic leukemias with MLL rearrangements. They identify recurrent activating mutations in tyrosine kinase, phosphatidylinositol 3-kinase and RAS pathway genes but find that these mutations were often present in minor subclones and lost at the time of relapse. Infant acute lymphoblastic leukemia (ALL) with MLL rearrangements (MLL-R) represents a distinct leukemia with a poor prognosis. To define its mutational landscape, we performed whole-genome, exome, RNA and targeted DNA sequencing on 65 infants (47 MLL-R and 18 non–MLL-R cases) and 20 older children (MLL-R cases) with leukemia. Our data show that infant MLL-R ALL has one of the lowest frequencies of somatic mutations of any sequenced cancer, with the predominant leukemic clone carrying a mean of 1.3 non-silent mutations. Despite this paucity of mutations, we detected activating mutations in kinase-PI3K-RAS signaling pathway components in 47% of cases. Surprisingly, these mutations were often subclonal and were frequently lost at relapse. In contrast to infant cases, MLL-R leukemia in older children had more somatic mutations (mean of 6.5 mutations/case versus 1.3 mutations/case, P = 7.15 × 10−5) and had frequent mutations (45%) in epigenetic regulators, a category of genes that, with the exception of MLL, was rarely mutated in infant MLL-R ALL.

1 March 2002 in Acta Haematologica
Verified
Journal Article
Closed access
PDF file
BJBertil Johansson
Bertil Johansson
TFThoas Fioretos
Thoas Fioretos
FMFelix Mitelman
Felix Mitelman
Chronic myeloid leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22 called the Philadelphia (Ph) chromosome. In 2–10% of the cases, this chimeric gene is generated by variant rearrangements, involving 9q34, 22q11, and one or several other genomic regions. All chromosomes have been described as participating in these variants, but there is a marked breakpoint clustering to chromosome bands 1p36, 3p21, 5q13, 6p21, 9q22, 11q13, 12p13, 17p13, 17q21, 17q25, 19q13, 21q22, 22q12, and 22q13. Despite their genetically complex nature, available data indicate that variant rearrangements do not confer any specific phenotypic or prognostic impact as compared to CML with a standard Ph chromosome. In most instances, the t(9;22), or a variant thereof, is the sole chromosomal anomaly during the chronic phase (CP) of the disease, whereas additional genetic changes are demonstrable in 60–80% of cases in blast crisis (BC). The secondary chromosomal aberrations are clearly nonrandom, with the most common chromosomal abnormalities being +8 (34% of cases with additional changes), +Ph (30%), i(17q) (20%), +19 (13%), –Y (8% of males), +21 (7%), +17 (5%), and monosomy 7 (5%). We suggest that all these aberrations, occurring in >5% of CML with secondary changes, should be denoted major route abnormalities. Chromosome segments often involved in structural rearrangements include 1q, 3q21, 3q26, 7p, 9p, 11q23, 12p13, 13q11–14, 17p11, 17q10, 21q22, and 22q10. No clear-cut differences as regards type and prevalence of additional aberrations seem to exist between CML with standard t(9;22) and CML with variants, except for slightly lower frequencies of the most common changes in the latter group. The temporal order of the secondary changes varies, but the preferred pathway appears to start with i(17q), followed by +8 and +Ph, and then +19. Molecular genetic abnormalities preceding, or occurring during, BC include overexpression of the BCR/ABL transcript, upregulation of the EVI1 gene, increased telomerase activity, and mutations of the tumor suppressor genes RB1, TP53, and CDKN2A. The cytogenetic evolution patterns vary significantly in relation to treatment given during CP. For example, +8 is more common after busulfan than hydroxyurea therapy, and the secondary changes seen after interferon-alpha treatment or bone marrow transplantation are often unusual, seemingly random, and occasionally transient. Apart from the strong phenotypic impact of addition of acute myeloid leukemia/myelodysplasia-associated translocations and inversions, such as inv(3)(q21q26), t(3;21)(q26;q22), and t(15;17)(q22;q12–21), in CML BC, only a few significant differences between myeloid and lymphoid BC are discerned, with i(17q) and TP53 mutations being more common in myeloid BC and monosomy 7, hypodiploidy, and CDKN2A deletions being more frequent in lymphoid BC. The prognostic significance of the secondary genetic changes is not uniform, although abnormalities involving chromosome 17, e.g., i(17q), have repeatedly been shown to be ominous. However, the clinical impact of additional cytogenetic and molecular genetic aberrations is most likely modified by the treatment modalities used.

6 June 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
HLHenrik Lilljebjörn
Henrik Lilljebjörn
RHRasmus Henningsson
Rasmus Henningsson
AHAxel Hyrenius-Wittsten
Axel Hyrenius-Wittsten
LOLinda Olsson
Linda Olsson
COChristina Orsmark-Pietras
Christina Orsmark-Pietras
TFThoas Fioretos
Thoas Fioretos
Fusion genes are potent driver mutations in cancer. In this study, we delineate the fusion gene landscape in a consecutive series of 195 paediatric B-cell precursor acute lymphoblastic leukaemia (BCP ALL). Using RNA sequencing, we find in-frame fusion genes in 127 (65%) cases, including 27 novel fusions. We describe a subtype characterized by recurrent IGH-DUX4 or ERG-DUX4 fusions, representing 4% of cases, leading to overexpression of DUX4 and frequently co-occurring with intragenic ERG deletions. Furthermore, we identify a subtype characterized by an ETV6-RUNX1-like gene-expression profile and coexisting ETV6 and IKZF1 alterations. Thus, this study provides a detailed overview of fusion genes in paediatric BCP ALL and adds new pathogenetic insights, which may improve risk stratification and provide therapeutic options for this disease.

28 November 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JLJian-Feng Li
Jian-Feng Li
YDYu-Ting Dai
Yu-Ting Dai
HLHenrik Lilljebjörn
Henrik Lilljebjörn
SSShu-Hong Shen
Shu-Hong Shen
BCBo-Wen Cui
Bo-Wen Cui
JHJinyan Huang
Jinyan Huang
Significance: In BCP ALL, molecular classification is used for risk stratification and influences treatment strategies. We reanalyzed the transcriptomic landscape of 1,223 BCP ALLs and identified 14 subgroups based on their transcriptional profiles. Eight of these (G1 to G8) are previously well-known subgroups, harboring specific genetic abnormalities. The sample size allowed the identification of six previously undescribed subgroups, consisting of cases harboring PAX5 or CRLF2 fusions (G9), PAX5 (p.P80R) mutations (G10), IKZF1 (p.N159Y) mutations (G11), either ZEB2 (p.H1038R) mutations or IGH–CEBPE fusions (G12), HLF rearrangements (G13), or NUTM rearrangements (G14). In addition, this study allowed us to determine the prognostic impact of several recently defined subgroups. This study suggests that RNA sequencing should be a valuable tool in the routine diagnostic workup for ALL.

1 November 1992 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
PÅPierre Åman
Pierre Åman
DRDavid Ron
David Ron
NMNils Mandahl
Nils Mandahl
TFThoas Fioretos
Thoas Fioretos
SHSverre Heim
Sverre Heim
FMFelix Mitelman
Felix Mitelman